Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Unicycive Therapeutics (UNCY) EBIAT (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of EBIAT readings, the most recent being -$21.5 million for Q4 2024.

  • On a quarterly basis, EBIAT fell 176.03% to -$21.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$36.7 million, a 20.25% decrease, with the full-year FY2025 number at -$26.6 million, up 27.7% from a year prior.
  • EBIAT hit -$21.5 million in Q4 2024 for Unicycive Therapeutics, down from -$4.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $9.9 million in Q2 2024 to a low of -$21.5 million in Q4 2024.
  • Median EBIAT over the past 3 years was -$4.8 million (2022), compared with a mean of -$7.1 million.
  • Biggest five-year swings in EBIAT: crashed 312.07% in 2023 and later soared 356.77% in 2024.
  • Unicycive Therapeutics' EBIAT stood at -$5.3 million in 2022, then plummeted by 46.36% to -$7.8 million in 2023, then tumbled by 176.03% to -$21.5 million in 2024.
  • The last three reported values for EBIAT were -$21.5 million (Q4 2024), -$4.1 million (Q3 2024), and $9.9 million (Q2 2024) per Business Quant data.